Wuhan Yzy Biopharma Co., Ltd.
Overview
Wuhan YZY Biopharma Co., Ltd. is a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies for the treatment of cancer-associated complications, cancer, and age-related ophthalmologic diseases. Established in 2010, the company has developed a pipeline of seven clinical-stage drug candidates targeting various cancers and eye diseases.
Therapeutic areas
API / Drug Master Files
Wuhan Yzy Biopharma Co., Ltd. holds 1 active (1 total) FDA Type II Drug Master File — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.
- L-A-GLYCERYLPHOSPHORYLCHOLINEActive2015-03-02
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Wuhan Yzy Biopharma Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.